168 related articles for article (PubMed ID: 38688749)
1. Modification of lipoprotein metabolism and function driving atherogenesis in diabetes.
Luciani L; Pedrelli M; Parini P
Atherosclerosis; 2024 Jul; 394():117545. PubMed ID: 38688749
[TBL] [Abstract][Full Text] [Related]
2. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
3. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
[TBL] [Abstract][Full Text] [Related]
5. Triglyceride-rich lipoproteins and cardiovascular diseases.
Xu D; Xie L; Cheng C; Xue F; Sun C
Front Endocrinol (Lausanne); 2024; 15():1409653. PubMed ID: 38883601
[TBL] [Abstract][Full Text] [Related]
6. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
7. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
Qamar A; Khetarpal SA; Khera AV; Qasim A; Rader DJ; Reilly MP
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1880-8. PubMed ID: 26069232
[TBL] [Abstract][Full Text] [Related]
8. Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis.
Amor AJ; Catalan M; Pérez A; Herreras Z; Pinyol M; Sala-Vila A; Cofán M; Gilabert R; Ros E; Ortega E
Atherosclerosis; 2016 Apr; 247():161-9. PubMed ID: 26921744
[TBL] [Abstract][Full Text] [Related]
9. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of Diabetic Dyslipidemia.
Hirano T
J Atheroscler Thromb; 2018 Sep; 25(9):771-782. PubMed ID: 29998913
[TBL] [Abstract][Full Text] [Related]
11. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
[TBL] [Abstract][Full Text] [Related]
12. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
13. Regulation of plasma triglycerides in insulin resistance and diabetes.
Ginsberg HN; Zhang YL; Hernandez-Ono A
Arch Med Res; 2005; 36(3):232-40. PubMed ID: 15925013
[TBL] [Abstract][Full Text] [Related]
14. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins.
Borggreve SE; De Vries R; Dullaart RP
Eur J Clin Invest; 2003 Dec; 33(12):1051-69. PubMed ID: 14636288
[TBL] [Abstract][Full Text] [Related]
15. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
[TBL] [Abstract][Full Text] [Related]
16. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
Taskinen MR; Björnson E; Kahri J; Söderlund S; Matikainen N; Porthan K; Ainola M; Hakkarainen A; Lundbom N; Fermanelli V; Fuchs J; Thorsell A; Kronenberg F; Andersson L; Adiels M; Packard CJ; Borén J
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
[TBL] [Abstract][Full Text] [Related]
17. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
18. Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM).
Raj R; Bhatti JS; Badada SK; Ramteke PW
Diabetes Metab Res Rev; 2015 Oct; 31(7):663-71. PubMed ID: 25470794
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.
Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I
Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210
[TBL] [Abstract][Full Text] [Related]
20. Management of triglycerides, non-high density lipoprotein cholesterol and high density lipoprotein cholesterol.
Zachariah G
Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S58-S64. PubMed ID: 37979723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
